Zydus Lifesciences Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences Limited has submitted to the exchanges a Regulation 31(4) disclosure signed by its promoters and promoter group entities for the financial year ended March 31, 2025. The disclosure, filed by individuals and entities such as Pankaj R. Patel, Sharvil P. Patel, Pritiben P. Patel, Zydus Family Trust, R B Patel Will Pankaj Trust, and several group firms/HUFs/LLPs, declares that none of them, along with persons acting in concert, have created any encumbrance (pledge, lien, or charge) on the equity shares of Zydus Lifesciences held by them. Several promoter group entities, including Cadila Laboratories, Cadmach Machinery, Aleta Hospitals LLP, and others, also confirmed they hold no shares of the company and have created no encumbrance.
This is a routine annual compliance filing under SEBI takeover norms and is a 'nil' disclosure — it signals that promoters have not pledged or otherwise encumbered their holdings during the year. For shareholders, this is a neutral, mildly positive indicator of promoter confidence and absence of any forced-sale risk from pledged shares.